Pomdoctor Limited
POMHealthcare|Medical - Pharmaceuticals|CN
$1.81
+0.42 (+30.22%)
Cash / Share
$0.24
Financials
Financial Snapshot
Market Cap
$15.5M
Enterprise Value
$168.2M
Revenue (TTM)
$345.0M
Net Income (TTM)
-$288.8M
Cash & Investments
$1.9M
Net Cash
-$64.5M
Free Cash Flow (TTM)
-$128.8M
Operating CF (TTM)
-$127.0M
Debt/Equity
-0.96
Cash Runway & Burn Rate
Cash on Hand
$1.9M
Quarterly Burn
$31.7M
Monthly Burn
$10.6M
Est. Runway
~0.1 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $10.6M | $12.9M | $2.2M | $2.5M | $6.7M | $7.7M | $9.6M | $1.9M | |
| Operating Cash Flow | -$59.4M | -$35.6M | -$15.7M | -$22.0M | -$45.8M | -$16.1M | -$148.5M | -$127.0M | |
| Free Cash Flow | -$59.6M | -$35.6M | -$15.7M | -$22.0M | -$45.9M | -$16.2M | -$149.5M | -$128.8M | |
| Capital Expenditure | -$199.9K | $21.17 | $0.00 | $0.00 | -$111.9K | -$37.8K | -$1.0M | -$1.8M | |
| Financing Cash Flow | $65.4M | $37.2M | $5.4M | $22.5M | $50.1M | $17.0M | $153.9M | $137.3M |
R&D Spending
R&D (TTM)
$80.1M
R&D Intensity
23.2%
R&D Growth vs Prior
+522.4%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.7M | $144.4M | $215.4M | $245.2M | $304.9M | $342.6M | $399.9M | $345.0M | |
| R&D Expense | $4.8M | $2.0M | $4.3M | $3.6M | $3.4M | $3.0M | $12.9M | $80.1M | |
| R&D % of Revenue | 2.6% | 1.4% | 2.0% | 1.5% | 1.1% | 0.9% | 3.2% | 23.2% | |
| SG&A | $135.7M | $298.7M | $103.0M | $54.9M | $56.0M | $68.2M | $155.9M | $269.6M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.7M | $144.4M | $215.4M | $245.2M | $304.9M | $342.6M | $399.9M | $345.0M | |
| Cost of Revenue | $108.2M | $89.5M | $162.9M | $190.4M | $266.1M | $294.9M | $347.6M | $304.7M | |
| Gross Profit | $76.5M | $54.9M | $52.5M | $54.9M | $38.7M | $47.7M | $52.3M | $40.3M | |
| R&D | $4.8M | $2.0M | $4.3M | $3.6M | $3.4M | $3.0M | $12.9M | $80.1M | |
| SG&A | $135.7M | $298.7M | $103.0M | $54.9M | $56.0M | $68.2M | $155.9M | $269.6M | |
| Operating Income | -$64.0M | -$245.8M | -$79.7M | -$3.6M | -$22.2M | -$25.8M | -$116.4M | -$255.9M | |
| Interest Expense | $9.5M | $14.3M | $16.3M | $16.0M | $13.8M | $13.0M | $12.9M | $895.7K | |
| Pretax Income | -$73.2M | -$262.3M | -$96.2M | -$19.8M | -$36.9M | -$37.4M | -$130.9M | -$294.2M | |
| Net Income | -$73.1M | -$262.2M | -$188.4M | -$125.5M | -$145.4M | -$143.4M | -$212.6M | -$288.8M | |
| EPS (Diluted) | -12.88 | -45.01 | -139.83 | -93.15 | -69.12 | -68.16 | -65.88 | -61.98 | |
| EBITDA | -$42.3M | -$224.2M | -$58.6M | -$3.8M | -$23.0M | -$24.3M | -$117.9M | -$255.5M | |
| Shares Out. (M) | 5.70 | 5.70 | 1.35 | 1.35 | 2.10 | 2.10 | 3.23 | 7.73 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.6M | $12.9M | $2.2M | $2.5M | $6.7M | $7.7M | $9.6M | $1.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $29.2M | $26.1M | $18.4M | $47.7M | $59.4M | $37.5M | $105.0M | $10.9M | |
| Total Assets | $98.9M | $77.3M | $19.3M | $48.6M | $66.3M | $46.2M | $107.6M | $11.2M | |
| Total Current Liabilities | $112.6M | $329.0M | $109.4M | $143.6M | $172.0M | $179.1M | $218.2M | $31.1M | |
| Long-Term Debt | $27.9M | $47.5M | $312.5M | $318.9M | $355.4M | $365.1M | $369.4M | $54.6M | |
| Total Liabilities | $151.2M | $386.0M | $1.80B | $1.95B | $2.03B | $2.14B | $588.9M | $85.8M | |
| Stockholders' Equity | -$52.3M | -$308.7M | -$1.85B | -$1.97B | -$2.12B | -$2.26B | -$454.0M | -$69.4M | |
| Retained Earnings | -$816.4M | -$1.08B | -$1.85B | -$1.97B | -$2.12B | -$2.26B | -$2.48B | -$398.9M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$59.4M | -$35.6M | -$15.7M | -$22.0M | -$45.8M | -$16.1M | -$148.5M | -$127.0M | |
| Capital Expenditure | -$199.9K | $21.17 | $0.00 | $0.00 | -$111.9K | -$37.8K | -$1.0M | -$1.8M | |
| Free Cash Flow | -$59.6M | -$35.6M | -$15.7M | -$22.0M | -$45.9M | -$16.2M | -$149.5M | -$128.8M | |
| Investing Cash Flow | -$180.8K | $25.6K | -$500.0K | $0.00 | -$111.9K | -$33.4K | -$1.6M | -$1.1M | |
| Financing Cash Flow | $65.4M | $37.2M | $5.4M | $22.5M | $50.1M | $17.0M | $153.9M | $137.3M | |
| Issuance of Stock | $59.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $163.9M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $5.7M | $37.2M | $5.4M | $22.5M | $52.3M | $17.0M | $14.1M | -$682.2K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.4M | $124.2M | |
| Net Change in Cash | $10.6M | $3.1M | -$10.7M | $474.7K | $4.2M | $846.6K | $1.9M | -$3.9M |
Dilution Tracker
Shares Outstanding
9M
5-Year Share Growth
-43.4%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 5.70 | 5.70 | 1.35 | 1.35 | 2.10 | 2.10 | 3.23 | 7.73 | |
| Change vs Prior % | — | 0.0% | -76.4% | 0.0% | 56.1% | 0.0% | 53.4% | 139.5% | |
| Stock Issuance | $59.7M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $163.9M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.4M | $124.2M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.4% | 38.0% | 24.4% | 22.4% | 12.7% | 13.9% | 13.1% | 11.7% | |
| Operating Margin % | -34.6% | -170.3% | -37.0% | -1.5% | -7.3% | -7.5% | -29.1% | -74.2% | |
| Net Margin % | -39.6% | -181.6% | -87.5% | -51.2% | -47.7% | -41.9% | -53.2% | -83.7% | |
| EBITDA Margin % | -22.9% | -155.3% | -27.2% | -1.6% | -7.5% | -7.1% | -29.5% | -74.0% | |
| FCF Margin % | -32.3% | -24.6% | -7.3% | -9.0% | -15.1% | -4.7% | -37.4% | -37.3% | |
| ROE % | 139.6% | 84.9% | 10.2% | 6.4% | 6.9% | 6.3% | 46.8% | 79.8% | |
| ROA % | -73.9% | -339.2% | -975.6% | -258.2% | -219.3% | -310.1% | -197.6% | -2573.4% | |
| ROIC % | -254.4% | 126.4% | 124.0% | 5.6% | 45.4% | 44.0% | 441.5% | 3098.7% | |
| R&D / Revenue % | 2.6% | 1.4% | 2.0% | 1.5% | 1.1% | 0.9% | 3.2% | 23.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -21.8% | 49.2% | 13.9% | 24.3% | 12.4% | 16.7% | |
| Gross Profit | 0.0% | -28.2% | -4.4% | 4.5% | -29.4% | 23.2% | 9.6% | |
| Operating Income | 0.0% | -284.2% | 67.6% | 95.5% | -519.0% | -15.9% | -351.2% | |
| Net Income | 0.0% | -258.9% | 28.1% | 33.4% | -15.8% | 1.4% | -48.3% | |
| EPS (Diluted) | 0.0% | -249.5% | -210.7% | 33.4% | 25.8% | 1.4% | 3.3% | |
| Operating Cash Flow | 0.0% | 40.1% | 55.9% | -40.4% | -108.0% | 64.8% | -820.5% | |
| Free Cash Flow | 0.0% | 40.3% | 55.9% | -40.4% | -108.5% | 64.8% | -824.6% | |
| R&D Expense | 0.0% | -57.6% | 111.0% | -16.2% | -6.0% | -10.9% | 328.5% | |
| SG&A Expense | 0.0% | 120.1% | -65.5% | -46.7% | 2.1% | 21.9% | 128.5% | |
| Total Assets | 0.0% | -21.8% | -75.0% | 151.8% | 36.4% | -30.3% | 132.7% | |
| Book Value / Share | 0.0% | -490.2% | -2335.1% | -6.8% | 33.8% | -6.8% | 85.0% | |
| Debt | 0.0% | 47.4% | 198.9% | 5.9% | 14.4% | 6.7% | 3.1% | |
| Diluted Shares | 0.0% | 0.0% | -76.4% | 0.0% | 56.1% | 0.0% | 53.4% |
Valuation
P/E (TTM)At Loss
P/S0.30
10Y Low / Med / High1.00 / 10.84 / 62.26
P/B-1.35
EV/EBITDAAt Loss
EV/Revenue0.49
10Y Low / Med / High2.11 / 12.10 / 62.96
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.24
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -130.69 | -35.05 | -10.98 | -17.90 | -24.83 | -25.89 | -1.88 | -0.19 | |
| P/S Ratio | 51.93 | 62.26 | 9.61 | 9.16 | 11.84 | 10.84 | 1.00 | 0.30 | |
| P/B Ratio | -183.20 | -29.12 | -1.12 | -1.14 | -1.70 | -1.64 | -0.88 | -1.35 | |
| EV/EBITDA | -228.48 | -40.54 | -41.12 | -684.17 | -174.71 | -170.83 | -7.16 | -0.66 | |
| EV/Revenue | 52.29 | 62.96 | 11.18 | 10.63 | 13.17 | 12.10 | 2.11 | 0.49 |
Analyst Estimates & Quality
Altman Z-Score
-95.62
Distress
Piotroski F-Score
3
Weak
Revenue Segments
By Product
| Segment | 2025 |
|---|---|
| Other Operating Segment | $399.9M |